Class summary at a glance.

Every drug in the Vitamin D Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $35.6Mcombined across class
Total Rx claims: 226K131K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Calcipotriene

Brand: Calcitrene · 226K Part D claims (CY24) · 131K beneficiaries · First FDA approval: 1996-10-01

5 generic mfrs 265 plans require PA

Low NADAC$1.10

→

Avg plan cost$1.65

Part D spend $35.6M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Calcipotriene and Betamethasone Dipropionate

Brand: ENSTILAR · — Part D claims (CY24) · First FDA approval: 2008-06-01

3 generic mfrs 60 plans require PA

Low NADAC$0.886

→

Avg plan cost$6.54

Part D spend — 7× spread, current vs floor

Class share

of class CY24 spend

View profile →

Calcipotriene, Betamethasone Dipropionate

Brand: Calcipotriene and Betamethasone Dipropionate · — Part D claims (CY24) · First FDA approval: 2020-01-30

Brand-only (no generics) 3 plans require PA

Low NADAC$1.72

→

Avg plan cost$2.28

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.